Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
ADJUTEC PHARMA AS
AS
Active
Org 923831762
Ullernchausséen 64, 0379
Oslo
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2019 · 6 years old
5 employees
Overvåg
Share
Norway
/
Companies
/
Research and experimental development on natural sciences and engineering
/
ADJUTEC PHARMA AS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Ledelse
Aktivt ansatte i selskabet
Name
Role
Member since
Current (1)
JL
Jethro Lee Holter
Chief Executive Officer
Chief Executive Officer
2025
Former (1)
BK
Bjørn Klem
Chief Executive Officer
Chief Executive Officer
2021 – 2025
Bestyrelse
Ikke-udøvende tilsyn
Name
Role
Member since
Current (6)
NR
Nicolaj Refshall Weiergang
Board of Directors
Board of Directors
2024
EF
Espen Franzon Amundsen
Board of Directors
Board of Directors
2024
KE
Kjell Erik Nordby
Board of Directors
Board of Directors
2021
ØK
Øyvind Kongstun Arnesen
Chairman
Chairman
2024
AF
Antonius Franciscus Berkien
Board of Directors
Board of Directors
2023
PR
Pål Rongved
Board of Directors
Board of Directors
2021
Former (3)
JE
Jonas Einarsson
Board of Directors
Board of Directors
2021 – 2024
JE
Jónas Einarsson
Board of Directors
Board of Directors
2023 – 2024
HT
Hege Tjørsvaag Brattebø
Board of Directors
Board of Directors
2024 – 2024
Aktionærer
Pr. seneste årsrapport
Shareholder
Type
Ownership
Votes
Since
Patias Innovation As
Company
49.15%
49.15%
2025
Kistefos As
Company
9.41%
9.41%
2025
Inven2 As
Company
5.39%
5.39%
2025
Helene Sundt As
Company
4.86%
4.86%
2025
Weiergangart As
Company
3.24%
3.24%
2025
Tryllebo As
Company
3.16%
3.16%
2025
Høse As
Company
3.08%
3.08%
2025
Cgs Holding As
Company
2.4%
2.4%
2025
Lemuren As
Company
2.33%
2.33%
2025
Weier As
Company
2.08%
2.08%
2025
Radforsk Investeringsstiftelse
Company
1.71%
1.71%
2025
Sundt As
Company
1.48%
1.48%
2025
Farvatn Venture As
Company
1.46%
1.46%
2025
Adjutec Pharma As
Company
1.44%
1.44%
2025
Jandersen Kapital As
Company
1.35%
1.35%
2025
Myrlid As
Company
1.35%
1.35%
2025
Wibo Consulting As
Company
1.11%
1.11%
2025
Ken Holding As
Company
1.08%
1.08%
2025
Star Kapital As
Company
1.03%
1.03%
2025
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on ADJUTEC PHARMA AS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network